Table 2 Univariate analysis of progression-free survival and disease-specific survival in advanced stage.

From: CD206+ tumor-associated macrophages promote proliferation and invasion in oral squamous cell carcinoma via EGF production

 

Progression-free

survival rate

Disease-specific

survival rate

HR (95% CI)

P value

HR (95% CI)

P value

Age (y)

<65 vs 65≦

1.52 (0.62–4.06)

0.36

1.72 (0.70–4.61)

0.24

Sex

Male vs female

1.02 (0.42–2.53)

0.96

1.05 (0.42–2.54)

0.91

Pathologic tumor status

pT1 + T2 vs T3 + T4

1.45 (0.54–3.57)

0.43

2.06 (0.77–5.09)

0.15

Pathologic node status

N- vs N+

0.38 (0.06–1.35)

0.15

0.36 (0.06–1.25)

0.12

Pathologic metastasis status

M0 vs M1

2.46 (0.70–6.74)

0.14

2.48 (0.71–6.77)

0.14

Stage

1 + 2 vs 3 + 4

1.05 (0.41–2.55)

0.91

1.34 (0.52–3.24)

0.53

WHO grade

1 vs 2 + 3

1.17 (0.46–2.84)

0.72

1.40 (0.55–3.39)

0.47

YK status

1 + 2 vs 3 + 4

3.03 (1.11–10.6)

0.03*

3.31 (1.21–11.6)

0.02*

EGF positive cells

Low vs high

1.67 (0.68–4.46)

0.26

1.78 (0.72–4.73)

0.21

CD163 positive cells

Low vs high

2.21 (0.85–5.58)

0.10

2.03 (0.83–5.42)

0.12

CD204 positive cells

Low vs high

2.32 (0.95–6.18)

0.06

2.14 (0.87–5.71)

0.09

CD206 positive cells

Low vs high

3.28 (1.1–14.1)

0.03*

3.29 (1.1–14.1)

0.03*

  1. Statistically significant differences between groups were determined by Cox proportional hazard model (*P < 0.05). HR, hazard ratio; CI, confidence interval.
Back to article page